| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Sep'17 | Jun'17 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues: | ||||||||||
Total revenues | ||||||||||
3,597 | 3,669 | 3,790 | 3,797 | 5,000 | 6,574 | 0 | 0 | 0 | 0 | 0 |
Operating expenses: | ||||||||||
Research and development | ||||||||||
42,895 | 44,330 | 44,660 | 44,849 | 49,054 | 48,788 | 0 | 0 | 0 | 0 | 0 |
General and administrative | ||||||||||
18,126 | 18,952 | 19,240 | 18,499 | 16,350 | 12,674 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | ||||||||||
61,021 | 63,282 | 63,900 | 63,348 | 65,404 | 61,462 | 0 | 0 | 0 | 0 | 0 |
Loss from operations | ||||||||||
-57,424 | -59,613 | -60,110 | -59,551 | -60,404 | -54,888 | 0 | 0 | 0 | 0 | 0 |
Other income | ||||||||||
2,015 | 2,203 | 2,385 | 2,435 | 2,084 | 1,607 | 0 | 0 | 0 | 0 | 0 |
Net loss and comprehensive loss | ||||||||||
-55,409 | -57,410 | -57,725 | -57,116 | -58,320 | -53,281 | 0 | 0 | 0 | 0 | 0 |
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) | ||||||||||
-0.34 | -0.41 | -0.44 | -0.36 | -0.50 | 1.79 | -0.43 | -1.83 | -2.17 | -1.56 | -1.55 |
Weighted-average number of common shares outstanding, basic and diluted (in shares) | ||||||||||
43,835 | 33,695 | 33,646 | 33,493 | 33,390 | 34,952 | 33,191 | 7,275 | 5,378 | 5,232 | 5,159 |
Collaboration revenue | ||||||||||
Total revenues | ||||||||||
- | - | 3,789 | 3,796 | - | 4,932 | 0 | 0 | 0 | - | - |
Grant revenue | ||||||||||
Total revenues | ||||||||||
- | - | - | - | - | 1,642 | 0 | 0 | 0 | - | - |